MNK - Mallinckrodt Public Limited Company

NYSE - Nasdaq Real Time Price. Currency in USD
21.94
-0.44 (-1.96%)
As of 2:30PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close22.38
Open22.29
Bid21.80 x 300
Ask21.82 x 300
Day's Range21.15 - 22.35
52 Week Range19.00 - 58.09
Volume2,807,447
Avg. Volume3,083,617
Market Cap2.08B
Beta1.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cramer's lightning round: Don't buy Mallinckrodt after it...
    CNBC Videos5 days ago

    Cramer's lightning round: Don't buy Mallinckrodt after it...

    Jim Cramer shared his take on callers' favorite stocks at lightning speed, including that of a pharmaceutical company.

  • Pharma company Mallinckrodt on pace for worst day ever, s...
    CNBC Videos13 days ago

    Pharma company Mallinckrodt on pace for worst day ever, s...

    CNBC’s Meg Tirrell reports on what’s driving shares of specialty pharma company Mallinckrodt lower.

  • See what the IHS Markit Score report has to say about Mallinckrodt Plc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    Short interest is high for MNK with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. The net inflows of $4.18 billion over the last one-month into ETFs that hold MNK are among the lowest of the last year and appear to be slowing.

  • Barrons.com5 days ago

    [$$] Two Lawsuits Hit Express Scripts Unit on Pricing

    A securities filing made Tuesday by Express Scripts Holdings (ESRX) disclosed two large lawsuits that claim its subsidiary United Biosource helped drugmakers market their products in violation of antitrust and anti-kickback laws. The allegations in those suits touch on issues that Barron’s covered in a 2015 story that described how UBC’s contracts to promote drugmakers’ high-priced products seemed to conflict with the mission of its pharmacy benefit management parent: that is, to keep a lid on America’s drug bills (“Express Scripts Unit’s Connection to High Priced Specialty Drugs,” November 21, 2015). Other companies also named as defendants in the two suits were Eli Lilly & Co. (LLY) and Mallinckrodt PLC (MNK), as well as the Covance unit of Laboratory Corp. of America Holdings (LH).

  • Cramer's lightning round: Sell Mallinckrodt after its 'nutty' acquisition of Acthar
    CNBC5 days ago

    Cramer's lightning round: Sell Mallinckrodt after its 'nutty' acquisition of Acthar

    Jim Cramer shared his take on callers' favorite stocks at lightning speed, including that of a pharmaceutical company.

  • Benzinga7 days ago

    Mallinckrodt Bull Turns Bear, Slashes Price Target By 66%

    With concerns about Acthar, which fetches Mallinckrodt PLC (NYSE: MNK ) roughly one-third of its revenues, UBS tempered its expectations. The Analyst & Rating UBS analyst Marc Goodman downgraded shares ...

  • TheStreet.com7 days ago

    Mallinckrodt Stock Lowered to 'Neutral' at UBS Over Persisting Concerns

    The firm did assign the stock a $24 price target, roughly $2 higher than Mallinckrodt's share price Monday morning.

  • Mallinckrodt Plc: Strong price momentum but will it sustain?
    Capital Cube10 days ago

    Mallinckrodt Plc: Strong price momentum but will it sustain?

    Categories: Yahoo FinanceMallinckrodt Plc relative valuation is UNDERVALUED and it has a fundamental analysis score of 41. Our analysis is based on comparing Mallinckrodt Plc with the following peers – Johnson & Johnson, Mylan N.V., Zogenix, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Depomed, Inc. and General Electric Company (JNJ-US, MYL-US, ZGNX-US, TEVA-US, DEPO-US and GE-US). Mallinckrodt ... Read more (Read more...)

  • Capital Cube12 days ago

    ETFs with exposure to Mallinckrodt Plc : November 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Mallinckrodt Plc Here are 5 ETFs with the largest exposure to MNK-US. Comparing the performance and risk of Mallinckrodt Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Benzinga12 days ago

    Here's Why Barclays Downgraded Mallinckrodt

    Specialty pharma company Mallinckrodt PLC (NYSE: MNK ) reported disappointing  results before the open Tuesday,with the weakness stemming from soft sales of its key drug Acthar, which fetched roughly 52 ...

  • Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3
    Zacks12 days ago

    Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3

    Mallinckrodt (MNK) sales and earnings declined in the third-quarter due to volume Acthar declines.

  • Barrons.com12 days ago

    Mallinckrodt: Look Out Below!

    Has Wall Street gone a bit overboard punishing Mallinckrodt (MNK). The drug maker’s share price continued to fall Wednesday, extending the gut-churning 35% selloff it suffered yesterday on the heels of a disappointing third quarter earnings report. Analysts at Goldman Sachs, Wells Fargo and Barclays all downgraded Mallinckrodt, retreating from their previously bullish calls and moving to the sidelines.

  • TheStreet.com12 days ago

    Here's Why Mallinckrodt Stock Plummeted to an All-Time Low

    Disappointing third-quarter results and a failure to boost sales in key medications are weighing on shares of Mallinckrodt.

  • Company News For Nov 8, 2017
    Zacks12 days ago

    Company News For Nov 8, 2017

    Companies In The News are: CAR,TRUE,VRX,MNK

  • MarketWatch12 days ago

    Mallinckrodt shares drop after Goldman downgrade

    Mallinckrodt PLC shares dropped 2.4% in premarket trade Wednesday after the company was downgraded to neutral by Goldman Sachs. The company reported third-quarter profit and revenue misses on Tuesday, ...

  • The Wall Street Journal13 days ago

    [$$] Why Mallinckrodt’s Woes Matter to All Drug Makers

    Pushback against high prices and a crackdown on opioid marketing fueled a nasty stock fall at drug maker Mallinckrodt. Other companies are at risk.

  • Barrons.com13 days ago

    Charting the Market: Mallinckrodt Tumbles 35%

    Oh Mallinckrodt (MNK). Sales of the drugmaker's controversial product H.P. Acthar Gel fell 5.6% in the September quarter, and Mallinckrodt warned that December sales would be lower, still. It said patients ...

  • Thomson Reuters StreetEvents11 days ago

    Edited Transcript of MNK earnings conference call or presentation 7-Nov-17 1:30pm GMT

    Q3 2017 Mallinckrodt Plc Earnings Call

  • Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel
    Zackslast month

    Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel

    Mallinckrodt plc (MNK) announced that it will initiate a new phase IV study on H.P. Acthar Gel as a therapy option in patients with symptomatic sarcoidosis.

  • See what the IHS Markit Score report has to say about Mallinckrodt Plc.
    Markitlast month

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    Short interest is moderately high for MNK with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding MNK totaled $3.99 billion.

  • Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy
    Zacks2 months ago

    Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy

    Mallinckrodt plc (MNK) entered into a licensing agreement with NeuroproteXeon for the development and commercialization of the latter's investigational, pharmaceutical-grade xenon gas for inhalation therapy.

  • Mallinckrodt Plc breached its 50 day moving average in a Bullish Manner : MNK-US : October 3, 2017
    Capital Cube2 months ago

    Mallinckrodt Plc breached its 50 day moving average in a Bullish Manner : MNK-US : October 3, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mallinckrodt Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Mallinckrodt (MNK) Closes InfaCare Pharmaceutical Buyout
    Zacks2 months ago

    Mallinckrodt (MNK) Closes InfaCare Pharmaceutical Buyout

    Mallinckrodt (MNK) acquires privately-held InfaCare Pharmaceutical Corporation to diversify portfolio.

  • Fighting the Toxic Nightmare Next Door
    Bloomberg2 months ago

    Fighting the Toxic Nightmare Next Door

    A radiation-riddled landfill in St. Louis, Trump’s EPA, and two moms who won’t let it go.